| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 676.76 | 21.6% |
| Total Income | 678.63 | 19.4% |
| Expenditure | 607.48 | 17.3% |
| PBT | 71.15 | 40.2% |
| Net Profit | 62.77 | 69.2% |
| OPM | 13.79% | 10.92pp |
| NPM | 9.25% | 2.73pp |
| EPS | 6.88 | 69.5% |
Aarti Drugs Reports 9% Q4FY25 Revenue Growth, Despite 5% Full-Year Decline
07 May 2025 · 7 May 2025, 02:20 am
Summary
Aarti Drugs Limited, a Mumbai based pharmaceutical company, has reported a 9% YoY growth in revenue for Q4FY25, reaching Rs. 678.6 crores. The EBITDA stood at Rs. 95.2 crores, a growth of 10% YoY, with an EBITDA margin of 14%. The PAT stood at Rs. 62.8 crores, an increase of 33% YoY, with a PAT margin of 9.2%. However, the full-year revenue showed a 5% decline. The API business contributed ~39% to total APl sales, and the formulation segment reported a 4% YoY decline in revenue. The company has also entered into a power purchase agreement and updated on the lifting of Import Alert 66-40 by US FDA.
Key Highlights
- 1
Revenue grew by 9% to Rs. 679 crores in Q4FY25
- 2
EBITDA stood at Rs. 95.2 crores with a margin of 14% in Q4FY25
- 3
PAT stood at Rs. 62.8 crores with a margin of 9.2% in Q4FY25
- 4
Full-year revenue showed a 5% decline in FY25
- 5
API business contributed ~39% to total APl sales
- 6
Formulation Segment reported a 4% YoY decline in revenue in Q4FY25
- 7
Company entered into a power purchase agreement
- 8
Import Alert 66-40 by US FDA has been lifted for the company's API manufacturing facility
Management Comments
Mr. Adhish Patil
CFO & COO, of Aarti Drugs Limited
In Q4 FY25, Revenues grew by 9% to Rs. 679 crores with EBITDA Margins improving to 14%. During the quarter, we witnessed strong global demand for APIs, driving a 15.5% growth in volumes, primarily led by exports. Benefiting from improved operating leverage and stable input costs, we achieved ~14.5% EBITDA Margins in the standalone business. FY25 was a challenging year, beginning with muted global demand and elevated raw material costs, which impacted overall performance. Greater than expected market volatility, particularly due to falling input prices, led to a 5% year-on-year revenue decline. Despite the challenges, the Company improved cost efficiency and operational discipline over the year, which helped maintain our EBITDA Margins at 12.6%.
Informational and educational content only. Not investment advice.